The Technical Analyst
HilleVax, Inc. [HLVX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
HilleVax, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.71% $12.30
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 611.32 mill |
| EPS: | -3.04 |
| P/E: | -4.05 |
| Earnings Date: | Jun 05, 2024 |
| SharesOutstanding: | 49.70 mill |
| Avg Daily Volume: | 0.147 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.05 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.69x |
| Company: PE -4.05 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.08 (-66.86%) $-8.22 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 11.31 - 13.29 ( +/- 8.07%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-04 | Frazier Life Sciences X, L.p. | Buy | 8 850 | Common Stock |
| 2024-04-03 | Kohli Aditya | Sell | 6 000 | Common Stock |
| 2024-04-04 | Kohli Aditya | Sell | 6 000 | Common Stock |
| 2024-04-05 | Kohli Aditya | Sell | 6 000 | Common Stock |
| 2024-03-28 | Mcloughlin Sean | Buy | 1 250 | Common Stock |
| INSIDER POWER |
|---|
| -19.53 |
| Last 76 transactions |
| Buy: 14 572 379 | Sell: 83 223 108 |
Forecast:
16:00 - $12.27
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $12.27
Forecast 2: 16:00 - $12.27
Forecast 3: 16:00 - $12.27
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $12.30 (3.71% ) |
| Volume | 0.273 mill |
| Avg. Vol. | 0.147 mill |
| % of Avg. Vol | 185.78 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HLVX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:26 | sell | $14.92 | N/A | Active |
|---|
HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Latest Press Releases
2024-03-20 16:00:00 - Press Release
Hillevax Reports Full Year 2023 Financial Results And Highlights Recent Company Progress
Topline data from nest-in1 phase 2b clinical study of hil-214 in infants expected in mid-2024 enrollment for nest-in1 study completed in q2 2023 $303.5 million of cash, cash equivalents and marketable securities as of december 31, 2023 boston, march 20, 2024 (globe newswire) -- hillevax, inc. (nasdaq: hlvx), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended december 31, 2023, highlighted recent progress and outlined key upcoming milestones for hil-214, the company's investigational virus-like particle (vlp) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis...
2024-02-05 16:05:00 - Press Release
Hillevax To Present At Guggenheim 6th Annual Biotechnology Conference
Boston, feb. 05, 2024 (globe newswire) -- hillevax, inc. (nasdaq: hlvx), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the guggenheim 6th annual biotechnology conference in new york, new york on wednesday, february 7, 2024 at 2:00 p.m. est. hil-214, hillevax's investigational virus-like particle (vlp) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing phase 2b study nest-in1 will be topics of discussion.
2024-01-18 07:00:00 - Press Release
Hillevax Announces Executive Management Appointment Of Sean Mcloughlin As Chief Operating Officer
Boston, jan. 18, 2024 (globe newswire) -- hillevax, inc. (nasdaq: hlvx), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of sean mcloughlin as chief operating officer. as part of a planned transition in connection with mr. mcloughlin's appointment, co-founder and current chief operating officer dr. aditya kohli will remain a full-time executive with the company as chief business officer, where he will be responsible for business development and corporate strategy.
2024-01-03 18:28:00 - Press Release
Hillevax To Present At The 42nd Annual J.p. Morgan Healthcare Conference
Boston, jan. 03, 2024 (globe newswire) -- hillevax, inc. (nasdaq: hlvx), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd annual j.p. morgan healthcare conference in san francisco, california on monday, january 8, 2024 at 4:30 p.m. est / 1:30 p.m. pst. hil-214, hillevax's investigational virus-like particle (vlp) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing phase 2b study nest-in1 will be topics of discussion.
2023-11-01 16:48:00 - Press Release
Hillevax To Present At Upcoming Investor Conferences
Boston, nov. 01, 2023 (globe newswire) -- hillevax, inc. (nasdaq: hlvx), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the guggenheim 5th annual inflammation, neurology & immunology conference in new york, new york on monday, november 6, 2023 at 3:10 p.m. est and at the stifel healthcare conference in new york, new york, on tuesday, november 14, 2023 at 11:30 a.m. est. hil-214, hillevax's investigational virus-like particle (vlp) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing phase 2b study nest-in1 will be topics of discussion.
Latest News
2024-02-05 16:05:00 - GlobeNewsWire
HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the Guggenheim 6th Annual Biotechnology Conference in New York, New York on Wednesday, February 7, 2024 at 2:00 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
2024-01-03 18:28:00 - GlobeNewsWire
HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 8, 2024 at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
2023-11-14 13:32:17 - Zacks Investment Research
HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade
HilleVax, Inc. (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-11-01 16:48:00 - GlobeNewsWire
HilleVax to Present at Upcoming Investor Conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York, New York on Monday, November 6, 2023 at 3:10 p.m. EST and at the Stifel Healthcare Conference in New York, New York, on Tuesday, November 14, 2023 at 11:30 a.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
2023-09-26 16:01:00 - GlobeNewsWire
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 2023 Cantor Global Healthcare Conference in New York, New York on Thursday, September 28, 2023 at 12:40 p.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
2023-08-30 19:32:15 - Seeking Alpha
HilleVax: Takeda's Norovirus Vaccine Spinout
HilleVax is developing a virus-like particle vaccine candidate, HIL-214, for norovirus-induced acute gastroenteritis. Norovirus is highly contagious and causes a significant disease burden, with millions affected and billions in costs. HIL-214 has shown promising safety and immunogenicity profiles in Phase I & II trials, with ongoing Phase 2b trials in infants.
2023-06-07 11:03:16 - Zacks Investment Research
Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 56.8% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-01-04 16:05:00 - GlobeNewsWire
HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023, at 4:30 p.m. EST / 1:30 p.m. PST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
2022-12-14 11:17:42 - Zacks Investment Research
After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2022-12-13 11:17:48 - Zacks Investment Research
Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)
HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.